Biology and treatment of myelodysplastic syndromes — developments in the past decade

  title={Biology and treatment of myelodysplastic syndromes — developments in the past decade},
  author={L Roel Willemze and Willem E. Fibbe and J. H. Frederik Falkenburg and Johanna C Kluin-Nelemans and Ph. M. Kluin and J. E. Landegent},
  journal={Annals of Hematology},
ConclusionsDuring the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable… CONTINUE READING


Publications referenced by this paper.

Myeloid but not lymphoid cells carry the 5 q deletion : PCR anaiysis of loss of heterozygosity using mini - repeat sequences on highly purified cell fractions

Kroef MJPL, WE Fibbe, +6 authors JE Landegent
  • Blood
  • 1993

A predictive model for the clinical response to low - dose AraC : a study of 102 patients with myelodysplastic syndromes or acute leukemia

E Hellstr0m-Lindberg, Robert K-H, +4 authors A Ost
  • Br J Haematol
  • 1992

A randomized phase - I / II multicenter study ( EORTC 06891 ) on rhIL - 3 in patients with myelodysplastic syndromes at relatively low risk of developing leukemia ( MDS - LR )

R Willemze, N vantierLely, +21 authors R Zittoun
  • Blood
  • 1992

Cytogenetic effects of cells derived from patients with myelodysplastic syndromes during treatment of hematopoietic growth factors

G Verhoef, H vandenBerghe, M Boogaerts
  • Leukemia
  • 1992